Treatment of established mammary tumors with the VEGF-R2-specific antibody DC101 alone inhibits tumor growth by decreasing angiogenesis and increasing apoptosis. DC101 treatment by itself induces tumor-specific T-cell responses, and integrating DC101 with vaccination enhances tumor-free survival and tumor-specific T-cell responses in the absence of immune tolerance. These findings establish the induction of tumor-specific T-cell responses as one consequence of VEGF-R2-targeting with DC101. For further details, please see Manning et al. on page 3951 in this issue.

[Table of Contents]